Hello. This module moves from the basic biology of GLP-1 to its effects on glucose, digestion, appetite, and reward. The earlier foundation was that insulin helps lower blood glucose, while glucagon signals the liver to release glucose. GLP-1 receptor agonists extend the action of a normally short-lived gut-hormone signal. Here, the question is more precise: how can that signal lower high glucose without ordinarily driving it too low—and why does the answer change when other medicines are involved?
The central idea is glucose dependence. The effects of GLP-1 receptor activation on insulin and glucagon change with the prevailing glucose level. Understanding that distinction will also help you evaluate claims that these medicines “cannot cause hypoglycaemia”: that wording is too absolute.
Two pancreatic signals, one blood-glucose balance
After a meal, glucose enters the bloodstream from the intestine. Pancreatic beta cells release insulin, which helps tissues take up glucose and restrains glucose production by the liver. Pancreatic alpha cells release glucagon, which encourages the liver to supply glucose to the blood. Glucagon is particularly important when glucose is falling or when food has not been eaten for some time.
The diagram below places GLP-1 alongside another gut hormone, GIP. For this lesson, follow the GLP-1 signal to the pancreas: it supports insulin secretion and inhibits glucagon release. Those actions work together. More insulin promotes glucose disposal; less glucagon reduces the liver’s contribution to circulating glucose.

For a short visual introduction, watch the glucose-control portion of Stanford Health Care’s GLP-1 Receptor Agonists: The Truth Behind the Trend:
GLP-1 Receptor Agonists: The Truth Behind the Trend
Stanford Health Care’s GLP-1 Receptor Agonists: The Truth Behind the Trend connects insulin, glucagon, and liver glucose release in an accessible overview.
Watch glucose control. Focus on why inhibiting glucagon can lower blood glucose even though glucagon does not itself remove glucose from the bloodstream. Stop as the discussion turns to gastric emptying; that mechanism is the subject of the next lesson.
The video gives the overall direction of the effects, but it leaves out an essential qualification. GLP-1 receptor activation does not simply hold insulin “on” and glucagon “off” at all glucose levels. The response depends on the state of the system.
What “glucose-dependent” means
When glucose is elevated, activating GLP-1 receptors amplifies the beta cell’s response to glucose. Insulin secretion rises relative to what it would have been at that same high glucose level without the added GLP-1 signal. At the same time, GLP-1 signalling suppresses glucagon secretion, so the liver receives less encouragement to release glucose.
As glucose returns toward a lower level, the insulin-stimulating effect diminishes. GLP-1 is therefore better understood as an amplifier of glucose-stimulated insulin release than as a switch that releases a fixed amount of insulin regardless of glucose. This also explains an initially puzzling observation: insulin measured after longer treatment need not remain higher than before treatment. If glucose has fallen substantially, the stimulus for insulin secretion has fallen too.
Read the pancreatic sections of the review Mechanisms of Action and Therapeutic Applications of GLP-1 and Dual GIP/GLP-1 Receptor Agonists for the evidence behind that distinction:
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
This review explains why GLP-1’s insulin effect depends on glucose and why its effect on glucagon differs when glucose is low. Read for the contrast between glucose conditions, rather than trying to memorize the cellular signalling details.
In Section 5, “Pharmacological effects of GIP, GLP-1 and their mimetics,” go to Section 5.1, “GIP and GLP-1 effects on pancreas.” In subsection 5.1.1, “Effects on pancreatic β-cell insulin secretion and survival,” read the opening explanation beginning insulin amplification. Then skip the intervening GIP-focused examples and read the paragraph beginning GLP-1 and glucose. Notice why a lower insulin measurement after glucose improves does not contradict an insulin-amplifying mechanism. Next, in subsection 5.1.2, “Effects on pancreatic α-cell glucagon release,” read from the opening comparison of GIP and GLP-1 through the GLP-1 contrast. Focus on the difference between glucagon suppression when glucose is normal or high and the response during hypoglycaemia. The later discussion of possible signalling between cells within the pancreatic islet is optional here.
There is an important nuance in the review: GLP-1 can suppress glucagon at normal as well as high glucose levels. “Glucose-dependent” does not mean the glucagon effect appears only above a sharp high-glucose cutoff. The crucial safety distinction is what happens when glucose becomes too low: the normal counter-response can increase glucagon, helping the liver release glucose rather than continuing to suppress that defence.
| Glucose situation | Insulin effect of GLP-1 receptor activation | Glucagon effect most relevant here |
|---|---|---|
| Elevated, such as after a meal in someone with high glucose | Amplifies glucose-stimulated insulin secretion | Suppresses glucagon, reducing a signal for liver glucose release |
| Falling toward a low level | Insulin-stimulating effect wanes | Suppression does not ordinarily block the glucagon rise that defends against hypoglycaemia |
This is a description of the GLP-1 pathway, not a promise about every circumstance in which a person might experience low blood glucose.
From mechanism to an observed drug effect
Semaglutide is one example of a GLP-1 receptor agonist: it activates the receptor targeted by the natural hormone, while persisting much longer than the natural signal. Its prescribing information is useful here because it separates the proposed mechanism from a specific observation made during low glucose.
highlights of prescribing information - accessdata.fda.gov
The semaglutide prescribing information describes its receptor action and reports what happened to insulin and counter-regulatory responses when glucose was experimentally lowered. Use it as evidence about this particular medicine, not as proof that every GLP-1 receptor agonist is identical.
In Section 12, “Clinical Pharmacology,” read subsection 12.1, “Mechanism of Action,” from receptor action. Then go to the “Glucose dependent insulin and glucagon secretion” part of the clinical-pharmacology discussion near Figure 2. Read the paragraph above Figure 2 and the sentence immediately below its caption, beginning low-glucose response. Notice that the label discusses both a glucagon rise and a fall in C-peptide, a marker of insulin secretion.
The induced-hypoglycaemia finding supports the mechanistic picture: in that study, semaglutide did not prevent the rise in glucagon or the decrease in insulin secretion that normally help defend against low glucose. It does not establish that hypoglycaemia is impossible. The other medicines a person takes can alter the balance.
Why combinations change the risk
Consider what happens if insulin is supplied as a medicine. Its glucose-lowering action does not automatically fade just because the current blood glucose has become low. Sulfonylureas, a class of insulin secretagogues, can also stimulate pancreatic insulin release in a way that is less tightly governed by the GLP-1 pathway’s glucose dependence.
Now add a GLP-1 receptor agonist. It can improve glucose control, but the separately supplied insulin or secretagogue may still exert a glucose-lowering effect as glucose falls. The pathway’s built-in moderation cannot be treated as a safeguard against all the effects of the combination. Food intake, activity, and other circumstances can further affect the balance between glucose entering and leaving the blood.
The warning in the semaglutide prescribing information states this distinction explicitly:
highlights of prescribing information - accessdata.fda.gov
Section 5.5 of the prescribing information explains why the low-glucose risk of a GLP-1 receptor agonist used alone should not be assumed to apply unchanged when it is combined with insulin or an insulin secretagogue.
Find Section 5.5, “Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin.” Read from the combination warning, stopping before Section 5.6, “Acute Kidney Injury Due to Volume Depletion.” Note which accompanying medicines the warning names and why a clinician may need to reassess their doses; this is not an instruction to change a medicine yourself.
A careful way to state the conclusion is: GLP-1 receptor agonists have a relatively low risk of hypoglycaemia when used without medicines that independently drive insulin action, but the risk rises when they are used with insulin or an insulin secretagogue such as a sulfonylurea. “Relatively low risk” is more accurate than “no risk,” and the combination matters more than the GLP-1 mechanism considered in isolation.
Key takeaways
GLP-1 receptor activation lowers elevated blood glucose through two coordinated pancreatic effects: it amplifies glucose-stimulated insulin secretion, and it reduces glucagon-driven liver glucose release. As glucose falls, the insulin effect wanes; during hypoglycaemia, glucagon can rise as part of the counter-response. That glucose dependence helps explain the relatively low hypoglycaemia risk of GLP-1 receptor agonists used without insulin-driving medicines. Insulin and sulfonylureas change the risk because their effects are not protected by that same degree of glucose dependence.
So far, the focus has been on pancreatic hormones and the liver. The next lesson follows a different route to post-meal glucose control: how slower gastric emptying changes the rate at which nutrients reach the intestine and glucose reaches the bloodstream.